{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T19:55:24Z","timestamp":1784145324494,"version":"3.55.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ackdjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1053\/j.ackd.2021.07.005","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T20:52:51Z","timestamp":1639601571000},"page":"371-377","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mineralocorticoid Receptor Antagonists\u2014Evidence for Kidney Protection, Trials With Novel Agents"],"prefix":"10.1053","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3748-2317","authenticated-orcid":false,"given":"Omar","family":"Al Dhaybi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George L.","family":"Bakris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1053\/j.ackd.2021.07.005_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0158765","article-title":"Global prevalence of chronic kidney disease - a systematic review and meta-analysis","volume":"11","author":"Hill","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"10.1053\/j.ackd.2021.07.005_bib2","first-page":"219","article-title":"2012 update on diabetic kidney disease: the expanding spectrum, novel pathogenic insights and recent clinical trials","volume":"103","author":"Fernandez Fernandez","year":"2012","journal-title":"Minerva Med"},{"issue":"9981","key":"10.1053\/j.ackd.2021.07.005_bib3","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(14)61601-9","article-title":"Worldwide access to treatment for end-stage kidney disease: a systematic review","volume":"385","author":"Liyanage","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"10.1053\/j.ackd.2021.07.005_bib4","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1053\/j.ajkd.2019.05.009","article-title":"Major Advancements in slowing diabetic kidney disease progression: focus on SGLT2 inhibitors","volume":"74","author":"Bakris","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ackd.2021.07.005_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11886-018-0943-5","article-title":"SGLT2 inhibitors and mechanisms of hypertension","volume":"20","author":"Briasoulis","year":"2018","journal-title":"Curr Cardiol Rep"},{"issue":"24","key":"10.1053\/j.ackd.2021.07.005_bib6","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"10166","key":"10.1053\/j.ackd.2021.07.005_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1053\/j.ackd.2021.07.005_bib8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/MNH.0000000000000290","article-title":"Mineralocorticoid antagonists in chronic kidney disease","volume":"26","author":"Dhaybi","year":"2017","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"5","key":"10.1053\/j.ackd.2021.07.005_bib9","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: Detection, evaluation, and management: a scientific statement from the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"issue":"10","key":"10.1053\/j.ackd.2021.07.005_bib10","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1053\/j.ackd.2021.07.005_bib11","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"issue":"Suppl A","key":"10.1053\/j.ackd.2021.07.005_bib12","doi-asserted-by":"crossref","first-page":"A20","DOI":"10.1093\/eurheartj\/suy030","article-title":"Barriers to guideline mandated renin-angiotensin inhibitor use: focus on hyperkalaemia","volume":"21","author":"Vijayakumar","year":"2019","journal-title":"Eur Heart J Suppl"},{"issue":"9","key":"10.1053\/j.ackd.2021.07.005_bib13","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"issue":"5","key":"10.1053\/j.ackd.2021.07.005_bib14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000503713","article-title":"Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial","volume":"50","author":"Bakris","year":"2019","journal-title":"Am J Nephrol"},{"issue":"5","key":"10.1053\/j.ackd.2021.07.005_bib15","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000503712","article-title":"Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial","volume":"50","author":"Ruilope","year":"2019","journal-title":"Am J Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2021.07.005_bib16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","article-title":"Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and Eplerenone in Patients with Essential Hypertension (ESAX-HTN Study)","volume":"75","author":"Ito","year":"2020","journal-title":"Hypertension"},{"key":"10.1053\/j.ackd.2021.07.005_bib50","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF02155834","article-title":"Isolierung eines neuen kristallisierten Hormons aus Nebennerien mit besonders hoher Wirksamkeit auf den Mineralsoffwechsel","volume":"9","author":"Simpson","year":"1953","journal-title":"Experientia"},{"key":"10.1053\/j.ackd.2021.07.005_bib51","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1126\/science.126.3281.1015","article-title":"Action of new steroids in blocking effects of aldosterone and desoxycorticosterone on salt","volume":"126","author":"Kagawa","year":"1957","journal-title":"Science"},{"issue":"Suppl 66","key":"10.1053\/j.ackd.2021.07.005_bib17","first-page":"12","article-title":"The story of spironolactones from 1957 to now: from sodium balance to inflammation","volume":"33","author":"Sabbadin","year":"2016","journal-title":"G Ital Nefrol"},{"issue":"1","key":"10.1053\/j.ackd.2021.07.005_bib18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1161\/HYPERTENSIONAHA.115.05674","article-title":"Low-dose mineralocorticoid receptor blockade prevents western diet-induced arterial stiffening in female mice","volume":"66","author":"DeMarco","year":"2015","journal-title":"Hypertension"},{"issue":"1-2","key":"10.1053\/j.ackd.2021.07.005_bib19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mce.2003.10.005","article-title":"The evolution of aldosterone antagonists","volume":"217","author":"Garthwaite","year":"2004","journal-title":"Mol Cell Endocrinol"},{"issue":"11","key":"10.1053\/j.ackd.2021.07.005_bib20","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.amjmed.2006.03.038","article-title":"Aldosterone blockade: an emerging strategy for abrogating progressive renal disease","volume":"119","author":"Epstein","year":"2006","journal-title":"Am J Med"},{"issue":"1-2","key":"10.1053\/j.ackd.2021.07.005_bib21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.mce.2003.10.008","article-title":"The 45-year story of the development of an anti-aldosterone more specific than spironolactone","volume":"217","author":"Menard","year":"2004","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"10.1053\/j.ackd.2021.07.005_bib22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"10.1053\/j.ackd.2021.07.005_bib23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.semnephrol.2014.04.008","article-title":"Prediction and management of hyperkalemia across the spectrum of chronic kidney disease","volume":"34","author":"Lazich","year":"2014","journal-title":"Semin Nephrol"},{"issue":"23","key":"10.1053\/j.ackd.2021.07.005_bib24","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.ackd.2021.07.005_bib25","doi-asserted-by":"crossref","first-page":"T125","DOI":"10.1530\/JOE-16-0600","article-title":"30 years OF the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development","volume":"234","author":"Kolkhof","year":"2017","journal-title":"J Endocrinol"},{"issue":"1","key":"10.1053\/j.ackd.2021.07.005_bib26","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","article-title":"Mineralocorticoid receptor antagonists for hypertension management in advanced chronic kidney disease: BLOCK-CKD trial","volume":"78","author":"Bakris","year":"2021","journal-title":"Hypertension"},{"issue":"4","key":"10.1053\/j.ackd.2021.07.005_bib28","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejphar.2015.06.015","article-title":"Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist","volume":"761","author":"Arai","year":"2015","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"10.1053\/j.ackd.2021.07.005_bib29","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1111\/bcp.13616","article-title":"Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects","volume":"84","author":"Kato","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1053\/j.ackd.2021.07.005_bib27","first-page":"137","article-title":"Pharmacological profile of KBP-5074, a novel non- steroidal mineralocorticoid receptor antagonist for the treatment of cardiorenal diseases","volume":"3","author":"Chow","year":"2017","journal-title":"J Drug Res Dev"},{"issue":"39","key":"10.1053\/j.ackd.2021.07.005_bib30","doi-asserted-by":"crossref","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","article-title":"A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule","volume":"285","author":"Fagart","year":"2010","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1053\/j.ackd.2021.07.005_bib31","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1517\/13543784.2015.1059819","article-title":"Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease","volume":"24","author":"Liu","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"issue":"8","key":"10.1053\/j.ackd.2021.07.005_bib32","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"Barfacker","year":"2012","journal-title":"ChemMedChem"},{"issue":"6","key":"10.1053\/j.ackd.2021.07.005_bib33","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1210\/me.2004-0537","article-title":"The ligand-dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms","volume":"19","author":"Hultman","year":"2005","journal-title":"Mol Endocrinol"},{"issue":"10008","key":"10.1053\/j.ackd.2021.07.005_bib34","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"10.1053\/j.ackd.2021.07.005_bib35","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/HJH.0b013e3283455ca5","article-title":"A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism","volume":"29","author":"Parthasarathy","year":"2011","journal-title":"J Hypertens"},{"issue":"5","key":"10.1053\/j.ackd.2021.07.005_bib36","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/MNH.0000000000000147","article-title":"Nonsteroidal antagonists of the mineralocorticoid receptor","volume":"24","author":"Kolkhof","year":"2015","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"Suppl 1","key":"10.1053\/j.ackd.2021.07.005_bib37","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.jash.2016.06.021","article-title":"Masked and nocturnal hypertension in the ARTS-DN ABPM sub-study with finerenone","volume":"10","author":"Ruilope","year":"2016","journal-title":"J Am Soc Hypertens"},{"issue":"7","key":"10.1053\/j.ackd.2021.07.005_bib38","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41371-019-0207-x","article-title":"Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study","volume":"33","author":"Ito","year":"2019","journal-title":"J Hum Hypertens"},{"issue":"4","key":"10.1053\/j.ackd.2021.07.005_bib39","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40265-019-01073-5","article-title":"Esaxerenone: first global approval","volume":"79","author":"Duggan","year":"2019","journal-title":"Drugs"},{"key":"10.1053\/j.ackd.2021.07.005_bib40","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","article-title":"Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD study","volume":"78","author":"Bakris","year":"2021","journal-title":"Hypertension"},{"issue":"2","key":"10.1053\/j.ackd.2021.07.005_bib41","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/ncpneph1004","article-title":"Renal aspirin: will all patients with chronic kidney disease one day take spironolactone?","volume":"5","author":"Bomback","year":"2009","journal-title":"Nat Clin Pract Nephrol"},{"issue":"8","key":"10.1053\/j.ackd.2021.07.005_bib42","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1210\/en.2008-0724","article-title":"Stroke therapy: is spironolactone the Holy Grail?","volume":"149","author":"Dorrance","year":"2008","journal-title":"Endocrinology"},{"issue":"3","key":"10.1053\/j.ackd.2021.07.005_bib43","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/cpt.758","article-title":"Renal targeted therapies of antihypertensive and cardiovascular drugs for patients with stages 3 through 5d kidney disease","volume":"102","author":"Ai Dhaybi","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1053\/j.ackd.2021.07.005_bib44","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1161\/HYPERTENSIONAHA.121.17005","article-title":"Cardiovascular protection with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in chronic kidney disease: a milestone achieved","volume":"77","author":"Sarafidis","year":"2021","journal-title":"Hypertension"},{"issue":"3","key":"10.1053\/j.ackd.2021.07.005_bib45","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2215\/CJN.04750908","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis","volume":"4","author":"Navaneethan","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.ackd.2021.07.005_bib46","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1097\/HJH.0000000000002187","article-title":"Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Alexandrou","year":"2019","journal-title":"J Hypertens"},{"issue":"31","key":"10.1053\/j.ackd.2021.07.005_bib47","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"issue":"27","key":"10.1053\/j.ackd.2021.07.005_bib48","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559521000549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559521000549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:02:36Z","timestamp":1761548556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559521000549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S1548559521000549"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2021.07.005","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mineralocorticoid Receptor Antagonists\u2014Evidence for Kidney Protection, Trials With Novel Agents","name":"articletitle","label":"Article Title"},{"value":"Advances in Chronic Kidney Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ackd.2021.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the National Kidney Foundation, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}